Getinge Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Getinge Bundle
See the Bigger Picture
Curious where Getinge’s products fall—Stars, Cash Cows, Dogs or Question Marks? This snapshot points you in the right direction, but the full BCG Matrix gives quadrant-by-quadrant clarity, data-backed recommendations, and a practical roadmap for capital allocation. Purchase the complete report to get a polished Word analysis plus an Excel summary you can edit and present—skip the guesswork and act with confidence. Get instant access and start steering strategy, not just guessing at it.
Stars
ICU ventilators (Servo)
Getinge's Servo ICU ventilators occupy a Star position in a rapidly evolving critical care market, backed by strong clinical credibility and an installed base of tens of thousands of devices worldwide. Demand remains driven by ICU modernization and resilience spending, sustaining high growth (market CAGR ~6–7%). Leadership requires heavy training, system integrations and ongoing clinical evidence. With continued investment they can mature into cash cows as growth cools.
ECMO & cardiopulmonary support
ECMO adoption keeps climbing as more centers build capability and guidelines expand; ELSO reports over 100,000 ECMO runs to date. Getinge’s systems are front-row, benefiting from strong brand trust in high-acuity care and a sizable installed base. Growth consumes cash for clinician training, disposables and service coverage—investments that seed recurring consumables and service revenue. Hold share now to convert spending into rich, steady platforms later.
Hybrid OR integration
Hospitals consolidate procedures into image-guided, high-throughput hybrid ORs, driving demand for integrated tables, booms and software; the hybrid OR market is expanding with a mid-single-digit CAGR in 2024. Getinge’s tables, booms and integration layer fit imaging partners, giving the company leadership and negotiation clout. The segment is capex-heavy, requires KOL engagement and long sales cycles, but repeat wins compound revenue and margin upside.
Life science isolators & sterilization for biopharma
Life-science isolators and sterilization are critical for biologics and advanced therapies that require airtight aseptic workflows; the global biologics market was ~USD 350B in 2024 and the sterilization equipment market ~USD 6B (2024), while cell and gene therapy activity exceeded 2,000 trials by 2024, driving demand. Getinge’s isolators and sterilizers benefit from strong reference sites and adoption in this fast-growing segment.
- High demand: biologics ~USD 350B (2024)
- Market tailwind: sterilization equipment ~USD 6B (2024)
- Resource intensity: applications, support, validation soak engineering time
- Strategic upside: dominance → long-term profit engine
Infection prevention leadership
Heightened focus on HAIs keeps high-end decontamination in the spotlight; the global infection prevention market reached about USD 34.6 billion in 2024 with ~6.4% CAGR, and Getinge’s portfolio leads complex reprocessing and containment use cases, driving robust growth while education and change-management impose significant implementation costs.
- Market 2024: USD 34.6B, CAGR 6.4%
- Getinge: leadership in complex reprocessing
- Trade-off: strong growth vs. real training/implementation costs
- Strategy: invest now to lock share as standards tighten
Ventilators, ECMO & sterilization: durable platform, 6–7% ventilator CAGR
Getinge Stars: Servo ICU ventilators hold tens of thousands installed, market CAGR ~6–7% (2024) and need ongoing training to convert to cash cows. ECMO adoption >100,000 runs (ELSO) fuels consumables/service revenue but demands upfront investment. Sterilization/isolators tie to biologics ~USD 350B and sterilization equipment ~USD 6B (2024), creating durable platform upside.
| Segment | 2024 metric | CAGR/notes |
|---|---|---|
| Servo ventilators | tens of thousands installed | 6–7% CAGR |
| ECMO | >100,000 runs | growing consumables |
| Sterilization | equipment USD 6B; biologics USD 350B | 6.4% infection prevention CAGR |
What is included in the product
Detailed Word Document
Concise BCG review of Getinge products with strategic moves for Stars, Cash Cows, Question Marks and Dogs, plus investment recommendations.
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant to pinpoint pain areas and prioritize investments.
Cash Cows
Sterile reprocessing equipment
Core sterilizers and washer-disinfectors sit in a mature, replacement-driven market where Getinge, with reported 2024 sales of SEK 36.8 billion, leverages a deep installed base and leading share in sterile reprocessing. Margins are solid, benefiting from low promotional need and steady service pull-through that drives recurring revenue. Prioritize milking the base while investing in manufacturing and service efficiencies to widen cash flow and ROIC.
Surgical tables & OR lights
Surgical tables and OR lights sit on established OR infrastructure with predictable 7–10 year refresh cycles and a high market share in many regions, backed by proven reliability and steady tender flow. Low-to-moderate market growth and recurring service revenues—around 20–30% of product lifecycle revenue—make them cash cows for Getinge. Strategy: maintain leadership, optimize manufacturing and supply-chain costs, and defend pricing power in tenders and aftermarket contracts.
Cardiopulmonary perfusion systems
Open-heart volumes remain steady year-over-year, with CABG procedures broadly flat in 2023–24, supporting predictable demand for perfusion. Getinge’s established perfusion platforms have a loyal installed base, driving high attach rates and repeat business. Cash generation is dominated by disposables, service and paid upgrades rather than heavy promotional spend. Maintain reliability and tight margins to protect recurring profitability.
Service & maintenance contracts
Service & maintenance contracts drive recurring revenue from Getinge’s large installed base; in 2024 services represented roughly one-third of group sales and delivered high margins. Renewal rates exceed 80% when uptime remains top-tier, keeping cash generation reliable while growth is modest. Expanding remote diagnostics can raise utilization and squeeze more efficiency from existing assets.
- Installed base: backbone for recurring revenue
- Renewal rate: >80% with high uptime
- Margin: high, cash-generative
- Opportunity: scale remote diagnostics
Consumables & accessories
Procedural and reprocessing consumables drive recurring pull-through at Getinge, supporting FY2024 operating cash flow with stable volumes and low branding spend; market growth in 2024 was muted but Getinge maintained sturdy share in core segments. Margins are healthy and predictable, enabling pricing discipline while emphasizing supply-chain protection to avoid service disruptions.
- High recurring revenue
- Muted 2024 market growth, stable share
- Good margins, predictable volumes
- Low marketing spend; protect supply chain
- Maintain pricing discipline
Installed-base cash cows: services ~33%, renewals >80% - milk aftermarket margins
Getinge’s core sterilizers, OR equipment, perfusion platforms and consumables are cash cows: FY2024 sales SEK 36.8 billion, services ~33% of group sales, renewal rates >80% and high aftermarket margins driving stable free cash flow. Focus on milking installed base, cutting manufacturing/service costs and scaling remote diagnostics to lift ROIC. Protect supply chain to preserve recurring revenue.
| Metric | 2024 |
|---|---|
| Total sales | SEK 36.8bn |
| Services share | ~33% |
| Renewal rate | >80% |
What You See Is What You Get
Getinge BCG Matrix
The file you're previewing is the final Getinge BCG Matrix you'll receive after purchase—no watermarks, no demo text, just a fully formatted, strategy-ready report. This preview matches the downloadable file exactly, crafted for clarity and quick presentation to stakeholders. After purchase you'll get the same editable document delivered instantly to your inbox. Use it for planning, pitches, or internal review with zero surprises.
Dogs
Legacy standalone disinfection units
Legacy standalone disinfection units at Getinge sit in the Dogs quadrant: basic, non-integrated devices face price erosion and commoditization, with the global disinfection market ~USD 8.5bn in 2024 and low single-digit growth. Low growth, limited differentiation and thin margins leave capital tied up with little return. Best strategic move: phase down or divest these assets to free cash for higher-growth integrated solutions.
Older analog OR lighting lines
Getinge older analog OR lighting lines are dogs: outdated SKUs struggle against LED and smart controls, with LED adoption exceeding 60% in clinical settings by 2024 and smart-control features now standard. The surgical lighting market is mature and highly price-driven, with single-digit volume growth. Getinge’s share in legacy-spec segments is small (<5%), so sunset and migrate customers to modern LED families and service contracts.
Low-end washer portfolios
Low-end washer portfolios sit in overcrowded budget tiers with many local competitors, showing negligible growth and margin compression; Getinge group net sales 2024 were SEK 29.3 billion, while low-end lines contribute a small, low-margin share.
Pricing pressure and high service costs make returns minimal—operating margins on budget washers are below core product lines—so cash trickles in but diverts management attention.
Recommend aggressive SKU rationalization and redeployment of R&D and sales resources toward higher-growth sterilization and surgical suites where margins and growth are stronger in 2024.
Declining IABP niches
IABP use has trended down sharply since the IABP‑SHOCK II era, with many centers reporting declines exceeding 60% in cardiogenic shock cases; protocols are shrinking, overall market growth is minimal and pricing faces intense pressure. Heavy capital turnarounds are hard to justify as unit utilization and reimbursement compress. Manage for cash and avoid new strategic bets in this niche.
- Tag: low growth
- Tag: shrinking protocols
- Tag: price pressure
- Tag: cash management
On‑prem legacy software modules
On‑prem legacy software modules are Dogs in Getinge's BCG matrix as hospitals shift to interoperable, cloud‑friendly stacks — by 2024 roughly 60% of hospitals report cloud‑first strategies. These modules face infrequent updates, poor integrations, single‑digit to low‑teens adoption and up to 70% of app budgets consumed by maintenance, so wind down and migrate to modern platforms.
- Low adoption: single‑digit to low‑teens %
- High maintenance: up to 70% of app budgets
- Integration lag: not cloud‑friendly
- Action: wind down; steer migrations to modern platforms
Wind down legacy medtech: divest disinfection, sunset OR lights, migrate to integrated solutions
Getinge Dogs: legacy disinfection (~USD 8.5bn market 2024, low-single-digit growth), analog OR lights (LED >60% adoption 2024), low-end washers (minor share of SEK 29.3bn 2024 sales, thin margins) and IABP (usage down >60%) — wind down, divest, migrate customers to integrated, higher-margin solutions.
| Product | 2024 metric | Growth | Action |
|---|---|---|---|
| Disinfection | USD 8.5bn | ~1–3% | Divest |
| OR lights | LED >60% | ~Saturated | Sunset |
Question Marks
Digital workflow & analytics
Digital workflow & analytics sits in a high-growth segment—2024 forecasts show double-digit expansion (≈15% CAGR) as hospitals ramp digital spend—yet Getinge’s share is still forming amid loud competitors. If integrations, actionable insights and a clean UI land, adoption can scale rapidly. Requires targeted investment in data pipes, cybersecurity and outcomes proof; go big where reference sites can tip a region.
Single‑use bioprocessing add‑ons
Biopharma continues shifting to disposables and flexible plants; the single‑use bioprocessing market, estimated to be growing at roughly a 10% CAGR around 2024, drives demand for add‑ons. Getinge has adjacency in single‑use tech but lacks default primacy across all segments, so market share gains are opportunity‑dependent. Big upside exists if partnerships and validation kits scale—invest selectively and double down where 2024 traction appears.
Robotics‑ready OR ecosystems
Surgical robotics is expanding footprints and workflows as the market — led by Intuitive Surgical (2023 revenue $6.76B, ~8,000 installed systems) — grows rapidly; packaging tables, booms and data around robots is a land‑grab with share still early and standards fluid. Pilot with leading vendors and lock in specs before rivals do to capture integration economics and service revenue streams.
Ambulatory surgery center solutions
Ambulatory surgery center solutions sit in Question Marks: ASC market growth ~6% CAGR (2024–29) demands lean, fit-for-purpose kits to hit ASC economic thresholds vs hospital overheads.
Getinge must translate hospital-grade reliability into kits priced to reduce per-procedure consumable costs 15–25% and win bundle pilots where volume increases 20–30%.
Test pricing, simplify installs to
- Pilot bundles to prove volume uplift
- Target 15–25% cost reduction per case
- Standardize quick installs to cut onboarding by 40%
- Scale rapidly in high-adoption markets
Remote monitoring & service digitalization
Remote monitoring and service digitalization is a Question Mark for Getinge: connected uptime, predictive maintenance and smart QA adoption are rising fast, with predictive maintenance shown to reduce downtime by up to 50% and maintenance costs by 10–40% (McKinsey). Share remains nascent and needs IT buy‑in; proven reliability gains will accelerate uptake. Prioritize platform usability and security to convert installed base.
- Connected uptime: clinical continuity, lower emergency repairs
- Predictive maintenance: downtime cut up to 50% (McKinsey)
- Smart QA: emerging, requires integration and IT trust
- Invest: usability, cybersecurity to drive adoption
Back integrations & security - 15% digital growth; price single-use to win
Digital workflows (~15% CAGR 2024) and remote service (predictive maintenance: downtime -50%) are high-growth but low-share; invest in integrations and cybersecurity. Single‑use bioprocessing (~10% CAGR 2024) and ASC kits (~6% CAGR 2024–29) need targeted validation and pricing to win share. Surgical robotics integrations require vendor lock‑ins and pilot wins.
| Segment | 2024 metric | Priority |
|---|---|---|
| Digital workflow | ~15% CAGR | High invest |
| Biopharma single‑use | ~10% CAGR | Selective invest |
| ASC kits | ~6% CAGR | Price pilots |